Introduction to Pharmaceutical Dosage Forms

Main ideas, concepts, and lessons

Purpose of pharmaceutical dosage forms

• Drugs may be bitter, insoluble, or have challenging physicochemical properties.
• The required dosage may be very small, so an appropriate delivery format is needed.
• Dosage forms are developed to make drugs easy to take (patient-compliant) across different populations, including:
  • Elderly, children, women
  • Patients with disease, trauma, or bedridden status
• The goal is to deliver the drug in a form that enables compatible administration, curing, and a healthy life.

What dosage forms are designed to achieve

• Enable delivery of Active Pharmaceutical Ingredients (APIs) (the chemical moieties responsible for pharmacological action) to the body in an efficacious, safe, and easy manner.
• Improve:
  • Ease of administration (e.g., patients may not tolerate injections)
  • Bioavailability, meaning the rate and extent of drug availability in the body:
    • Aim to maximize drug reaching the body and minimize wastage.
    • Parenteral dosage forms generally provide ~100% bioavailability because they go directly to blood.
    • Non-parenteral routes typically do not ensure 100% bioavailability.
  • Pharmacokinetics to improve therapeutic response
    • Example: for poorly soluble drugs, a suspension can increase availability and therapeutic effect.

Major types of dosage forms

1. Solid
   • Examples: capsules, powders, granules
2. Liquid
   • Used to improve compliance (e.g., elderly difficulty swallowing; children may avoid solids)
   • Helps with physicochemical issues (e.g., high dose and solubility problems)
   • Forms: solution, syrup, suspension, emulsion
3. Semi-solid (generally topical)
   • Examples: ointments, creams, gels, pastes
4. Gaseous / fluidized
   • Examples: aerosols, deodorants, inhalers, nebulizers
   • Can produce local or systemic effects.

Key factors when designing dosage forms

• Drug nature and stability
  • If the drug is unstable (e.g., moisture-sensitive), a liquid may not be appropriate; a solid may be preferred.
  • Instability during shelf life (manufacturing/transport/storage) can influence selection.
  • Even if given as a solid, it may be solubilized in the body and quickly absorbed.
• Patient age and condition
  • Example: bedridden patients may not be suitable for solid forms.
• Route of administration
  • Choose what’s most comfortable: IV, oral, topical, etc.
  • The best route may vary depending on the disease condition.
• Onset and duration of action
  • For immediate effect (e.g., trauma), parenterals/IV are used for rapid blood infusion.
  • Oral dosing generally delays response due to time needed for absorption.
• Market/regulatory context
  • Target region (e.g., US vs UK) affects dosage form categories and ingredients.

Regulatory approval and development process (methodology/list)

• Regulatory approval is critical for commercialization; a product must be:
  • Safe
  • Efficacious
  • Compliant with regulatory standards
• Regulatory bodies require dosage form development through four stages:
  1. Testing on animals plus cell line studies
  2. Clinical trials in humans to assess safety and efficacy
  3. Regulatory submission
  4. Marketing approval after data verification, followed by:
     • Post-marketing surveillance (ongoing monitoring for safety and efficacy)

Regulatory bodies mentioned

• US FDA
• EMA (European Medicines Agency)
• World Health Organization
• In India: Indian FDA

Manufacturing/production workflow (methodology/list)

• Do not jump directly to industrial scale. Instead:
  1. Develop the formulation in R&D (fine-tune composition and process)
  2. Optimize unit operations for scale-up (e.g., mixing, granulation)
  3. Quality testing at mass production scale
  4. Ensure compliance of:
     • Raw materials
     • Intermediates
     • Finished dosage forms
  5. Pack and label properly to deliver the drug safely:
     • Control moisture (can degrade drug)
     • Control temperature (can affect drug stability)

Speakers or sources featured (as identified in the subtitles)

• No specific individual name is provided. The subtitles reflect a single instructor/speaker welcoming viewers and explaining course content.
• Regulatory sources/body names (institutions mentioned):
  • US FDA
  • EMA (European Medicines Agency)
  • World Health Organization
  • Indian FDA